Omalizumab for the treatment of chronic inducible urticaria in 80 patients
Br J Dermatol
.
2021 Jan;184(1):167-168.
doi: 10.1111/bjd.19425.
Epub 2020 Sep 2.
Authors
V Exposito-Serrano
1
,
L Curto-Barredo
2
,
P Aguilera Peiro
3
,
S Gómez Armayones
3
,
E Serra-Baldrich
4
,
J Spertino
4
,
M Bonfill Ortí
5
,
I Figueras Nart
5
,
G Melé-Ninot
6
,
C Baliu-Piqué
7
,
A Sala Cunill
8
,
M Labrador-Horrillo
8
,
A Guilabert Vidal
9
,
N Fernández Chico
1
,
A M Giménez-Arnau
2
Affiliations
1
Departments of Dermatology at, Department of Dermatology, Hospital Universitari Parc Taulí. Sabadell.
2
Department of Dermatology, Hospital del Mar.
3
Department of Dermatology, Hospital Clínic de Barcelona.
4
Department of Dermatology, Hospital de la Santa Creu i Sant Pau.
5
Department of Dermatology, Hospital de Bellvitge.
6
Department of Dermatology, Hospital Universitari Sagrat Cor.
7
Department of Dermatology, Hospital d'Igualada-Consorci Sanitari de l'Anoia.
8
Department of Dermatology, Allergology Department, Hospital Universitari Vall d'Hebron.
9
Department of Dermatology, Hospital General de Granollers, Spain.
PMID:
32730636
DOI:
10.1111/bjd.19425
No abstract available
Publication types
Letter
MeSH terms
Anti-Allergic Agents* / therapeutic use
Chronic Disease
Chronic Urticaria*
Humans
Omalizumab / adverse effects
Treatment Outcome
Urticaria* / drug therapy
Substances
Anti-Allergic Agents
Omalizumab